Ad is loading...
ATAI
Price
$1.68
Change
+$0.07 (+4.35%)
Updated
Nov 25 closing price
121 days until earnings call
GRCE
Price
$3.37
Change
-$0.00 (-0.00%)
Updated
Oct 25 closing price
Ad is loading...

ATAI vs GRCE

Header iconATAI vs GRCE Comparison
Open Charts ATAI vs GRCEBanner chart's image
ATAI Life Sciences
Price$1.68
Change+$0.07 (+4.35%)
Volume$1.52M
CapitalizationN/A
Grace Therapeutics
Price$3.37
Change-$0.00 (-0.00%)
Volume$27.81K
CapitalizationN/A
ATAI vs GRCE Comparison Chart
Loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GRCE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ATAI vs. GRCE commentary
Nov 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a StrongBuy and GRCE is a StrongBuy.

COMPARISON
Comparison
Nov 26, 2024
Stock price -- (ATAI: $1.68 vs. GRCE: $3.44)
Brand notoriety: ATAI and GRCE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 108% vs. GRCE: 172%
Market capitalization -- ATAI: $281.91M vs. GRCE: $34.88M
ATAI [@Biotechnology] is valued at $281.91M. GRCE’s [@Biotechnology] market capitalization is $34.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $468.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileGRCE’s FA Score has 0 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • GRCE’s FA Score: 0 green, 5 red.
According to our system of comparison, ATAI is a better buy in the long-term than GRCE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 6 TA indicator(s) are bullish while GRCE’s TA Score has 7 bullish TA indicator(s).

  • ATAI’s TA Score: 6 bullish, 4 bearish.
  • GRCE’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, GRCE is a better buy in the short-term than ATAI.

Price Growth

ATAI (@Biotechnology) experienced а +0.60% price change this week, while GRCE (@Biotechnology) price change was +8.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.76%. For the same industry, the average monthly price growth was -2.17%, and the average quarterly price growth was +8.74%.

Reported Earning Dates

ATAI is expected to report earnings on Mar 27, 2025.

Industries' Descriptions

@Biotechnology (+3.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATAI($282M) has a higher market cap than GRCE($34.9M). ATAI (19.149) and GRCE (19.031) have similar YTD gains . GRCE has higher annual earnings (EBITDA): -16.06M vs. ATAI (-124.33M). ATAI has more cash in the bank: 85.9M vs. GRCE (15.2M). ATAI has higher revenues than GRCE: ATAI (331K) vs GRCE (0).
ATAIGRCEATAI / GRCE
Capitalization282M34.9M808%
EBITDA-124.33M-16.06M774%
Gain YTD19.14919.031101%
P/E RatioN/AN/A-
Revenue331K0-
Total Cash85.9M15.2M565%
Total Debt23.8MN/A-
FUNDAMENTALS RATINGS
ATAI vs GRCE: Fundamental Ratings
ATAI
GRCE
OUTLOOK RATING
1..100
265
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
10053
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
3943
P/E GROWTH RATING
1..100
23100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRCE's Valuation (54) in the Pharmaceuticals Other industry is in the same range as ATAI (80) in the Miscellaneous Commercial Services industry. This means that GRCE’s stock grew similarly to ATAI’s over the last 12 months.

GRCE's Profit vs Risk Rating (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for ATAI (100) in the Miscellaneous Commercial Services industry. This means that GRCE’s stock grew somewhat faster than ATAI’s over the last 12 months.

GRCE's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as ATAI (98) in the Miscellaneous Commercial Services industry. This means that GRCE’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Price Growth Rating (39) in the Miscellaneous Commercial Services industry is in the same range as GRCE (43) in the Pharmaceuticals Other industry. This means that ATAI’s stock grew similarly to GRCE’s over the last 12 months.

ATAI's P/E Growth Rating (23) in the Miscellaneous Commercial Services industry is significantly better than the same rating for GRCE (100) in the Pharmaceuticals Other industry. This means that ATAI’s stock grew significantly faster than GRCE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAIGRCE
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
60%
View a ticker or compare two or three
Ad is loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GRCE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANTMX10.250.06
+0.59%
American Century Intl Sm-Md Cp G
BKDEX10.330.05
+0.49%
BlackRock Defensive Advantage EM K
TMIRX10.620.05
+0.47%
Transamerica Mid Cap Growth R
JACFX19.44-0.01
-0.05%
JHancock Mid Cap Growth NAV
BPTRX188.78-2.29
-1.20%
Baron Partners Retail

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with FATE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
+4.35%
FATE - ATAI
48%
Loosely correlated
+5.68%
NTLA - ATAI
47%
Loosely correlated
+3.43%
COUR - ATAI
45%
Loosely correlated
+11.11%
ALLO - ATAI
45%
Loosely correlated
+3.17%
VCYT - ATAI
45%
Loosely correlated
+3.81%
More

GRCE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRCE has been loosely correlated with IMVT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GRCE jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRCE
1D Price
Change %
GRCE100%
+4.88%
IMVT - GRCE
38%
Loosely correlated
+0.07%
SLNO - GRCE
38%
Loosely correlated
-0.97%
CYTK - GRCE
37%
Loosely correlated
+2.34%
SCNI - GRCE
31%
Poorly correlated
-0.28%
ATAI - GRCE
30%
Poorly correlated
+4.35%
More